Research programme: lung disorders therapy - Emergent BioDefense Operations Lansing/University of Maryland

Drug Profile

Research programme: lung disorders therapy - Emergent BioDefense Operations Lansing/University of Maryland

Alternative Names: Research programme: mucin release inhibitors - Emergent BioDefense Operations Lansing/University of Maryland; Research programme: polycationic peptides - Emergent BioDefense Operations Lansing/University of Maryland

Latest Information Update: 01 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Maryland, Baltimore
  • Developer Emergent BioDefense Operations Lansing; University of Maryland, Baltimore
  • Class
  • Mechanism of Action Mucin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma; Bronchiectasis; Bronchitis; Cystic fibrosis

Most Recent Events

  • 16 Jun 2003 The assets of Antex Biologics and Antex Pharma have been acquired by BioPort Corporation
  • 14 Nov 2002 This programme is still in active development
  • 06 Oct 2000 Preclinical development for Asthma in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top